Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Using PBPK Modeling to Predict Drug Exposure and Support Dosage Adjustments in Patients With Renal Impairment: An Example With Lamivudine.

Shah K, Fischetti B, Cha A, Taft DR.

Curr Drug Discov Technol. 2019 Feb 14. doi: 10.2174/1570163816666190214164916. [Epub ahead of print]

PMID:
30767745
2.

Effect of Gender on the Pharmacokinetics of ON 123300, A Dual Inhibitor of ARK5 and CDK4/6 for the Treatment of Cancer, in Rats.

Mudunuru J, Ren C, Taft DR, Maniar M.

Eur J Drug Metab Pharmacokinet. 2019 Aug;44(4):531-538. doi: 10.1007/s13318-019-00542-2.

PMID:
30701428
3.

Real-World Experience With Higher-Than-Recommended Doses of Lamivudine in Patients With Varying Degrees of Renal Impairment.

Fischetti B, Shah K, Taft DR, Berkowitz L, Bakshi A, Cha A.

Open Forum Infect Dis. 2018 Sep 10;5(10):ofy225. doi: 10.1093/ofid/ofy225. eCollection 2018 Oct.

4.

Application of physiologically based pharmacokinetic modeling to predict drug disposition in pregnant populations.

Jogiraju VK, Avvari S, Gollen R, Taft DR.

Biopharm Drug Dispos. 2017 Oct;38(7):426-438. doi: 10.1002/bdd.2081. Epub 2017 Jul 13.

PMID:
28474821
5.

Evaluating the Potential for Delivery of Irinotecan via the Buccal Route: Physicochemical Characterization and In Vitro Permeation Assessment Across Porcine Buccal Mucosa.

Shah V, Bellantone RA, Taft DR.

AAPS PharmSciTech. 2017 Apr;18(3):867-874. doi: 10.1208/s12249-016-0578-z. Epub 2016 Jun 30.

PMID:
27363416
6.

Phase 1 study of intravenous rigosertib (ON 01910.Na), a novel benzyl styryl sulfone structure producing G2/M arrest and apoptosis, in adult patients with advanced cancer.

Ohnuma T, Lehrer D, Ren C, Cho SY, Maniar M, Silverman L, Sung M, Gretz HF 3rd, Benisovich V, Navada S, Akahoho E, Wilck E, Taft DR, Roboz J, Wilhelm F, Holland JF.

Am J Cancer Res. 2013 Jun 20;3(3):323-38. Print 2013.

7.

Determination of intestinal permeability of rigosertib (ON 01910.Na, Estybon): correlation with systemic exposure.

White MP, Babayeva M, Taft DR, Maniar M.

J Pharm Pharmacol. 2013 Jul;65(7):960-9. doi: 10.1111/jphp.12057. Epub 2013 Mar 25.

PMID:
23738723
8.

Disposition of ON 01210.Na (Ex-RAD(R)), a novel radioprotectant, in the isolated perfused rat liver: probing metabolic inhibition to increase systemic exposure.

Tamhane M, Maniar M, Ren C, Benzeroual KE, Taft DR.

J Pharm Sci. 2013 Feb;102(2):732-40. doi: 10.1002/jps.23391. Epub 2012 Dec 4.

PMID:
23212688
9.

Radioprotective effects of ON 01210.Na upon oral administration.

Suman S, Datta K, Doiron K, Ren C, Kumar R, Taft DR, Fornace AJ Jr, Maniar M.

J Radiat Res. 2012;53(3):368-76. Epub 2012 May 11.

10.

Aristolochic acid I metabolism in the isolated perfused rat kidney.

Priestap HA, Torres MC, Rieger RA, Dickman KG, Freshwater T, Taft DR, Barbieri MA, Iden CR.

Chem Res Toxicol. 2012 Jan 13;25(1):130-9. doi: 10.1021/tx200333g. Epub 2011 Dec 14.

11.

Renal excretion of apricitabine in rats: ex vivo and in vivo studies.

Babayeva M, Cox S, White MP, Taft DR.

Eur J Drug Metab Pharmacokinet. 2011 Sep;36(3):141-50. doi: 10.1007/s13318-011-0038-9. Epub 2011 Apr 6.

PMID:
21744041
12.

Effects of formulation and route of administration on the systemic availability of Ex-RAD®, a new radioprotectant, in preclinical species.

Chun AW, Freshwater RE, Taft DR, Gillum AM, Maniar M.

Biopharm Drug Dispos. 2011 Mar;32(2):99-111. doi: 10.1002/bdd.741. Epub 2011 Jan 14.

PMID:
21341279
13.

Renal excretion of clofarabine: assessment of dose-linearity and role of renal transport systems on drug excretion.

Ajavon AD, Bonate PL, Taft DR.

Eur J Pharm Sci. 2010 Jun 14;40(3):209-16. doi: 10.1016/j.ejps.2010.03.014. Epub 2010 Mar 25.

PMID:
20347037
14.

Comparative renal excretion of VX-702, a novel p38 MAPK inhibitor, and methotrexate in the perfused rat kidney model.

Tamhane M, Chakilam AR, Jayaraj A, Thakkar V, Taft DR.

Drug Dev Ind Pharm. 2010 Mar;36(3):315-22. doi: 10.3109/03639040903154200.

PMID:
20170280
15.

Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent.

Chun AW, Cosenza SC, Taft DR, Maniar M.

Cancer Chemother Pharmacol. 2009 Dec;65(1):177-86. doi: 10.1007/s00280-009-1022-9. Epub 2009 May 24.

PMID:
19466411
16.

Renal excretion of emtricitabine II. effect of trimethoprim on emtricitabine excretion: In vitro and in vivo studies.

Nakatani-Freshwater T, Taft DR.

J Pharm Sci. 2008 Dec;97(12):5411-20. doi: 10.1002/jps.21369.

PMID:
18351642
17.

Renal excretion of emtricitabine I: effects of organic anion, organic cation, and nucleoside transport inhibitors on emtricitabine excretion.

Nakatani-Freshwater T, Taft DR.

J Pharm Sci. 2008 Dec;97(12):5401-10. doi: 10.1002/jps.21370.

PMID:
18351632
18.

Application of the isolated perfused rat kidney model to assess gender effects on drug excretion.

Taft DR, Dontabhaktuni A, Babayeva M, Nakatani-Freshwater T, Savant IA.

Drug Dev Ind Pharm. 2006 Sep;32(8):919-28.

PMID:
16954104
19.

Effects of trimethoprim on the clearance of apricitabine, a deoxycytidine analog reverse transcriptase inhibitor, and Lamivudine in the isolated perfused rat kidney.

Nakatani-Freshwater T, Babayeva M, Dontabhaktuni A, Taft DR.

J Pharmacol Exp Ther. 2006 Nov;319(2):941-7. Epub 2006 Aug 22.

PMID:
16926264
20.

The isolated perfused rat kidney model: a useful tool for drug discovery and development.

Taft DR.

Curr Drug Discov Technol. 2004 Jan;1(1):97-111.

PMID:
16472223
21.

Stability of sotalol hydrochloride in extemporaneously prepared oral suspension formulations.

Sidhom MB, Rivera N, Almoazen H, Taft DR, Kirschenbaum HL.

Int J Pharm Compd. 2005 Sep-Oct;9(5):402-6.

PMID:
23925139
22.

Measuring drug concentrations using pulsatile microdialysis: theory and method development in vitro.

Kabir MA, Taft DR, Joseph CK, Bellantone RA.

Int J Pharm. 2005 Apr 11;293(1-2):171-82.

PMID:
15778055
23.

Characterization of pentamidine excretion in the isolated perfused rat kidney.

Poola NR, Kalis M, Plakogiannis FM, Taft DR.

J Antimicrob Chemother. 2003 Sep;52(3):397-404. Epub 2003 Jul 29.

PMID:
12888599
24.

In vitro evaluation of the release of albuterol sulfate from polymer gels: effect of fatty acids on drug transport across biological membranes.

Chisty MN, Bellantone RA, Taft DR, Plakogiannis FM.

Drug Dev Ind Pharm. 2002 Nov;28(10):1221-9.

PMID:
12476868
25.

A novel HPLC assay for pentamidine: comparative effects of creatinine and inulin on GFR estimation and pentamidine renal excretion in the isolated perfused rat kidney.

Poola NR, Bhuiyan D, Ortiz S, Savant IA, Sidhom M, Taft DR, Kirschenbaum H, Kalis M.

J Pharm Pharm Sci. 2002 May-Aug;5(2):135-45.

26.
27.

Alternative high-performance liquid chromatographic assay for p-aminohippuric acid (PAH): effect of aging on PAH excretion in the isolated perfused rat kidney.

Savant IA, Kalis M, Almoazen H, Ortiz SR, AbuTarif M, Taft DR.

J Pharm Biomed Anal. 2001 Dec;26(5-6):687-99.

PMID:
11600282
28.
29.

Blood disposition and urinary excretion kinetics of methazolamide following oral administration to human subjects.

Taft DR, Nordt S, Iyer GR, Schwenk MH.

Biopharm Drug Dispos. 1998 Sep;19(6):373-80.

PMID:
9737818
30.
31.
32.

Evidence for reversible sequestration of morphine in rat liver.

Matheny CJ, Taft DR, Brouwer KL, Pollack GM.

Biochem Pharmacol. 1996 Aug 23;52(4):535-41.

PMID:
8759025
33.

Concentration-dependent tubular secretion of acetazolamide and its inhibition by salicylic acid in the isolated perfused rat kidney.

Taft DR, Chapron DJ, Fournier DJ, Sweeney KR.

Drug Metab Dispos. 1996 Apr;24(4):456-61.

PMID:
8801061
34.

Renal disposition and drug interaction screening of (-)-2'-deoxy-3'-thiacytidine (3TC) in the isolated perfused rat kidney.

Sweeney KR, Hsyu PH, Statkevich P, Taft DR.

Pharm Res. 1995 Dec;12(12):1958-63.

PMID:
8786973

Supplemental Content

Support Center